Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Severe Asthma Attack (FASTER)
NCT04617171Phase 2Unknown
- Sponsor
- Singapore General Hospital
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Benralizumab with Placebo (2 arms). Primary endpoint: Time to first exacerbation at 52 weeks. Status: unknown.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04617171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617171.